Abiopharma

REIN THERAPEUTICS, INC. (RNTX)

Symbol	RNTX
Name	REIN THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	285 SUMMER STREET,UNIT 101, BOSTON, Massachusetts, 02210, United States
Telephone	+1 617 995-0900
Fax	—
Email	—
Website	https://www.reintx.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001420565
Description	Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Companys lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis). Additional info from NASDAQ: Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Companys lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).

2026-06-08 10:18

New Form DEFA14A - Rein Therapeutics, Inc. Filed: 2026-06-08 AccNo: 0001193125-26-260812 Size: 2 MB

2026-06-08 10:18

New Form ARS - Rein Therapeutics, Inc. Filed: 2026-06-08 AccNo: 0001193125-26-260814 Size: 1 MB

2026-06-08 10:18

New Form DEF 14A - Rein Therapeutics, Inc. Filed: 2026-06-08 AccNo: 0001193125-26-260809 Size: 5 MB

2026-05-29 00:15

VON RICKENBACH JOSEF H 🟢 acquired 47.1K shares of Rein Therapeutics, Inc. (RNTX) at $1.07 Transaction Date: May 21, 2026 | Filing ID: 245832

2026-05-28 17:44

New Form PRE 14A - Rein Therapeutics, Inc. Filed: 2026-05-28 AccNo: 0001193125-26-245389 Size: 5 MB

2026-05-13 12:47

WINDSOR JAMES BRIAN 🟡 adjusted position in 125.0K shares (1 derivative) of Rein Therapeutics, Inc. (RNTX) at $1.17 Transaction Date: Apr 30, 2026 | Filing ID: 220718

2026-05-08 12:33

New Form SCHEDULE 13G/A - Rein Therapeutics, Inc. Filed: 2026-05-08 AccNo: 0001697316-26-000012 Size: 101 KB

2026-05-08 10:24

New Form SCHEDULE 13G - Rein Therapeutics, Inc. Filed: 2026-05-08 AccNo: 0001104659-26-057607 Size: 15 KB

2026-05-07 19:19

New Form SCHEDULE 13G - Rein Therapeutics, Inc. Filed: 2026-05-07 AccNo: 0002073679-26-000049 Size: 103 KB

2026-05-06 14:30

New Form SCHEDULE 13G - Rein Therapeutics, Inc. Filed: 2026-05-06 AccNo: 0000935836-26-000227 Size: 6 KB

No clinical trials found for this company.

No clinical products found for this company.